[
    [
        {
            "time": "",
            "original_text": "安图生物：大股东安图实业减持约1194万股 减持股份",
            "features": {
                "keywords": [
                    "安图生物",
                    "大股东",
                    "安图实业",
                    "减持",
                    "1194万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "安图生物：大股东安图实业减持约1194万股 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "安图生物(603658.SH)：安图实业减持期过半 累计减持2.77%股份 减持股份数量",
            "features": {
                "keywords": [
                    "安图生物",
                    "安图实业",
                    "减持",
                    "2.77%",
                    "股份数量"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "安图生物(603658.SH)：安图实业减持期过半 累计减持2.77%股份 减持股份数量",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "安图生物：控股股东累计减持2.77%股份 减持股份数量",
            "features": {
                "keywords": [
                    "安图生物",
                    "控股股东",
                    "减持",
                    "2.77%",
                    "股份数量"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "安图生物：控股股东累计减持2.77%股份 减持股份数量",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "安图生物获医疗器械注册证，短期内对经营业绩影响较小",
            "features": {
                "keywords": [
                    "安图生物",
                    "医疗器械",
                    "注册证",
                    "经营业绩",
                    "短期内"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物获医疗器械注册证，短期内对经营业绩影响较小",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝尔生物拟创业板上市：业绩增长较为稳健，商誉减值压力犹存",
            "features": {
                "keywords": [
                    "贝尔生物",
                    "创业板",
                    "上市",
                    "业绩增长",
                    "商誉减值",
                    "压力"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝尔生物拟创业板上市：业绩增长较为稳健，商誉减值压力犹存",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]